Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 12/2015

01-12-2015 | Literatur kommentiert

Die adjuvante Nachbestrahlung reduziert die Lokalrezidivrate auch beim prognostisch günstigen DCIS der Brust signifikant

Authors: Dr. med. René Pahl, Prof. Dr. med. Jürgen Dunst

Published in: Strahlentherapie und Onkologie | Issue 12/2015

Login to get access

Auszug

McCormick B, Winter K, Hudis C et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709–715 …
Literature
1.
Boyages J, Delaney G, Taylor R (1999) Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 85:616–628CrossRefPubMed
2.
Cuzick J, Sestak I, Pinder SE et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ-DCIS-trial. Lancet Oncol 12:21–29CrossRefPubMed
3.
Houghton JD, George WD, Cuzick J et al (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in UK, Australia and New Zealand: randomized controlled trial. Lancet 362:95–102CrossRefPubMed
4.
Hughes LL, Wang M, Page DL et al (2009) Local excision alone without irradiation for ductal carcinoma in situ oft he breast: a trial oft he Eastern Cooperative Oncology Group. J Clin Oncol 27:5319–5324PubMedCentralCrossRefPubMed
5.
McCormick B, Winter K, Hudis C et al (2015) RTOG 9804: a prospective randomized trial forgood-risk ductal carcinoma in situ comparingradiotherapy with observation. J Clin Oncol 33:709–715CrossRefPubMed
6.
Petrelli F, Barni S (2011) Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol 100:195–199CrossRefPubMed
7.
Staley H, McCallum I, Bruce J (2012) Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10:CD007847PubMed
8.
Solin LJ, Gray R, Hughes LL et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J ClinOncol 2015; JCO.2015.60.8588.
Metadata
Title
Die adjuvante Nachbestrahlung reduziert die Lokalrezidivrate auch beim prognostisch günstigen DCIS der Brust signifikant
Authors
Dr. med. René Pahl
Prof. Dr. med. Jürgen Dunst
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 12/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0906-3

Other articles of this Issue 12/2015

Strahlentherapie und Onkologie 12/2015 Go to the issue

Literatur kommentiert

Hodgkin-Lymphom in Kindheit oder Jugend: Keine niedrigere Mutterschaftsrate nach Bestrahlungen außerhalb des Beckens

Original Article

VMAT to arclet plan conversion in a treatment planning system

Original Article

Comparison of CT number calibration techniques for CBCT-based dose calculation

Original Article

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas

Letter to the Editor

Reply to: Comment on Dornoff et al.: re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Literatur kommentiert

Update zur kombinierten Radio-, Radiochemo- und alleinigen Chemotherapie bei der multimodalen Therapie des Nasopharynxkarzinoms – eine MAC-NPC-Metaanalyse